Author(s) |
(Date) |
Paper Title |
Citation |
Model Type |
Applications |
Full Text |
| RAB van Waterschoot, et al. Mouse over for full list RAB van Waterschoot, R ter Heine, E Wagenaar, CMM van der Kruijssen, RW Rooswinkel, ADR Huitema, JH Beijnen, AH Schinkel |
(2010) | Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir | British Journal of Pharmacology (2010), 160, 1224–1233 | |||
| Vlaming ML, et al. Mouse over for full list Vlaming ML, Mohrmann K, Wagenaar E, de Waart DR, Elferink RP, Lagas JS, van Tellingen O, Vainchtein LD, Rosing H, Beijnen JH, Schellens JH, Schinkel AH |
(2006) | Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. | J. Pharmacol. Exp. Ther. 318(1):319-27 | |||
| Nezasa K, et al. Mouse over for full list Nezasa K, Tian X, Zamek-Gliszczynski MJ, Patel NJ, Raub TJ, Brouwer KL |
(2006) | Altered hepatobiliary disposition of 5 (and 6)-carboxy-2',7'-dichlorofluorescein in Abcg2 (Bcrp1) and Abcc2 (Mrp2) knockout mice. | Drug Metab. Dispos. 34(4):718-23 | |||
| Chu XY, et al. Mouse over for full list Chu XY, Strauss JR, Mariano MA, Li J, Newton DJ, Cai X, Wang RW, Yabut J, Hartley DP, Evans DC, Evers R |
(2006) | Characterization of mice lacking the multidrug resistance protein MRP2 (ABCC2). | J. Pharmacol. Exp. Ther. 317(2):579-89 |
Welcome! Tell us a little about yourself